| Entry |
|
|---|
| Name |
Naproxen and esomeprazole magnesium;
Vimovo (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Component |
Naproxen [DR: D00118], (Esomeprazole magnesium [DR: D01984] | Esomeprazole magnesium dihydrate [DR: D11114])
|
|---|
| Class |
|
|---|
| Remark |
|
|---|
| Efficacy |
Anti-infammatory, Antirheumatic |
|---|
| Disease |
Gastric ulcer [DS: H01634] Rheumatoid arthritis [DS: H00630] Ankylosing spondylitis [DS: H01674] Juvenile idiopathic arthritis [DS: H01672] |
|---|
| Comment |
Naproxen is a substrate of CYP2C9 and CYP1A2.
Esomeprazole is metabolized by CYP2C19 with some contribution from CYP3A4.
|
|---|
| Metabolism |
Enzyme: CYP2C9 [HSA: 1559], CYP1A2 [HSA: 1544], CYP2C19 [HSA: 1557]; CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01AE Propionic acid derivatives
M01AE52 Naproxen and esomeprazole
D11576 Naproxen and esomeprazole magnesium <US>
USP drug classification [BR:br08302]
Analgesics
Nonsteroidal Anti-inflammatory Drugs
Esomeprazole Magnesium/ Naproxen
D11576 Naproxen and esomeprazole magnesium
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
D11576 Naproxen and esomeprazole magnesium
DG01642 CYP2C9 substrate
D11576 Naproxen and esomeprazole magnesium
DG01639 CYP2C19 substrate
D11576 Naproxen and esomeprazole magnesium
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D11576 Naproxen and esomeprazole magnesium
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11576
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
